Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Autotherapies: Enhancing Endogenous Healing and Regeneration.

Lumelsky N, O'Hayre M, Chander P, Shum L, Somerman MJ.

Trends Mol Med. 2018 Nov;24(11):919-930. doi: 10.1016/j.molmed.2018.08.004. Epub 2018 Sep 10. Review.

PMID:
30213702
2.

The homozygous CX3CR1-M280 mutation impairs human monocyte survival.

Collar AL, Swamydas M, O'Hayre M, Sajib MS, Hoffman KW, Singh SP, Mourad A, Johnson MD, Ferre EM, Farber JM, Lim JK, Mikelis CM, Gutkind JS, Lionakis MS.

JCI Insight. 2018 Feb 8;3(3). pii: 95417. doi: 10.1172/jci.insight.95417. eCollection 2018 Feb 8.

3.

Oral Health Disparities: A Perspective From the National Institute of Dental and Craniofacial Research.

Fischer DJ, O'Hayre M, Kusiak JW, Somerman MJ, Hill CV.

Am J Public Health. 2017 May;107(S1):S36-S38. doi: 10.2105/AJPH.2016.303622. No abstract available.

4.

Genetic evidence that β-arrestins are dispensable for the initiation of β2-adrenergic receptor signaling to ERK.

O'Hayre M, Eichel K, Avino S, Zhao X, Steffen DJ, Feng X, Kawakami K, Aoki J, Messer K, Sunahara R, Inoue A, von Zastrow M, Gutkind JS.

Sci Signal. 2017 Jun 20;10(484). pii: eaal3395. doi: 10.1126/scisignal.aal3395.

5.

The NIH's Funding to US Dental Institutions from 2005 to 2014.

Ferland CL, O'Hayre M, Knosp WM, Fox CH, Horsford DJ.

J Dent Res. 2017 Jan;96(1):10-16. doi: 10.1177/0022034516680555.

PMID:
28033063
6.

Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells.

O'Hayre M, Inoue A, Kufareva I, Wang Z, Mikelis CM, Drummond RA, Avino S, Finkel K, Kalim KW, DiPasquale G, Guo F, Aoki J, Zheng Y, Lionakis MS, Molinolo AA, Gutkind JS.

Oncogene. 2016 Jul 21;35(29):3771-80. doi: 10.1038/onc.2015.442. Epub 2015 Nov 30.

7.

Insights into β2-adrenergic receptor binding from structures of the N-terminal lobe of ARRDC3.

Qi S, O'Hayre M, Gutkind JS, Hurley JH.

Protein Sci. 2014 Dec;23(12):1708-16. doi: 10.1002/pro.2549. Epub 2014 Sep 26.

8.

Novel insights into G protein and G protein-coupled receptor signaling in cancer.

O'Hayre M, Degese MS, Gutkind JS.

Curr Opin Cell Biol. 2014 Apr;27:126-35. doi: 10.1016/j.ceb.2014.01.005. Epub 2014 Feb 6. Review.

9.

Structural and biochemical basis for ubiquitin ligase recruitment by arrestin-related domain-containing protein-3 (ARRDC3).

Qi S, O'Hayre M, Gutkind JS, Hurley JH.

J Biol Chem. 2014 Feb 21;289(8):4743-52. doi: 10.1074/jbc.M113.527473. Epub 2013 Dec 30.

10.

The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.

O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS.

Nat Rev Cancer. 2013 Jun;13(6):412-24. doi: 10.1038/nrc3521. Epub 2013 May 3. Review.

11.

Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL).

O'Hayre M, Niederst M, Fecteau JF, Nguyen VM, Kipps TJ, Messmer D, Newton AC, Handel TM.

Leukemia. 2012 Jul;26(7):1689-92. doi: 10.1038/leu.2012.6. Epub 2012 Jan 12. No abstract available.

12.

Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).

Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D.

Mol Med. 2012 Feb 10;18:19-28. doi: 10.2119/molmed.2011.00164.

13.

Emerging concepts and approaches for chemokine-receptor drug discovery.

O'Hayre M, Salanga CL, Handel TM, Hamel DJ.

Expert Opin Drug Discov. 2010 Nov;5(11):1109-22. Review.

14.

Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ.

Blood. 2011 Jan 20;117(3):882-9. doi: 10.1182/blood-2010-04-282400. Epub 2010 Nov 15.

15.

Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.

O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein PC, Handel TM.

PLoS One. 2010 Jul 22;5(7):e11716. doi: 10.1371/journal.pone.0011716.

16.

Phosphoproteomic analysis of chemokine signaling networks.

O'Hayre M, Salanga CL, Dorrestein PC, Handel TM.

Methods Enzymol. 2009;460:331-46. doi: 10.1016/S0076-6879(09)05216-1.

PMID:
19446733
17.

Modulation of chemokine receptor activity through dimerization and crosstalk.

Salanga CL, O'Hayre M, Handel T.

Cell Mol Life Sci. 2009 Apr;66(8):1370-86. doi: 10.1007/s00018-008-8666-1. Review.

18.

Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment.

O'Hayre M, Salanga CL, Handel TM, Allen SJ.

Biochem J. 2008 Feb 1;409(3):635-49. doi: 10.1042/BJ20071493. Review.

PMID:
18177271
19.

TGF-beta signaling and its effect on glutaminase expression in LLC-PK1-FBPase+ cells.

Andratsch M, Feifel E, Taylor L, O'Hayre M, Schramek H, Curthoys NP, Gstraunthaler G.

Am J Physiol Renal Physiol. 2007 Sep;293(3):F846-53. Epub 2007 Jun 27.

20.

Effects of constitutively active and dominant negative MAPK kinase (MKK) 3 and MKK6 on the pH-responsive increase in phosphoenolpyruvate carboxykinase mRNA.

O'Hayre M, Taylor L, Andratsch M, Feifel E, Gstraunthaler G, Curthoys NP.

J Biol Chem. 2006 Feb 3;281(5):2982-8. Epub 2005 Nov 30.

Supplemental Content

Loading ...
Support Center